natural killer cell
Overview
Natural killer (NK) cells are lymphocytes of the innate immune system that function as key effector cells in cancer surveillance and anti-tumor immunity. Distinct from T lymphocytes and other adaptive immune cells, NK cells are activated in response to transformed cells and can adopt multiple functional states, including enhanced "trained" states induced by microbial exposure that confer long-lasting protection against cancer metastasis. These cells mediate their cytotoxic functions through direct cell killing and through antibody-dependent cellular cytotoxicity via FcγRIIIa receptor engagement, and their activity can be modulated through diverse mechanisms including physical exercise, immunomodulatory compounds, and engineered therapeutics.
NK cell function is regulated by underlying metabolic and mitochondrial processes, and their dysfunction—induced by radiation exposure, environmental factors, or lipid metabolism reprogramming in the tumor microenvironment—can significantly impair anti-tumor immune responses. Therapeutic strategies to enhance NK cell-mediated immunity include engineered chimeric antigen receptor (CAR)-NK cell approaches and immunomodulatory interventions targeting regulatory pathways such as PD-1/PD-L1. In clinical applications including allogeneic hematopoietic stem cell transplantation for hematologic malignancies, NK cells function synergistically with T cells to provide durable anti-tumor immunity and support immune reconstitution.
Recent Publications Summary
Recent publications have examined natural killer (NK) cells in a range of immunological and therapeutic contexts, including cancer immunotherapy, exercise physiology, bacterial training, transplantation, and toxicology. Several studies focused on strategies to enhance NK-cell antitumor activity, such as a TIGIT-targeted IL-12 fusion protein that selectively localized to tumors and activated intratumoral NK and CD8+ T cells, producing strong tumor control in multiple mouse models with improved systemic safety relative to wild-type IL-12 42302794Jun. In parallel, pharmacologic glycoengineering of Fcγ receptor IIIa improved antibody-dependent tumor clearance through FcγRIIIa- and NK cell-dependent pathways, while a review highlighted ongoing translational and regulatory advances in CAR-NK cell therapies, including iPSC-derived manufacturing and expansion into autoimmune disease 42034063Apr.
Other studies described ways to potentiate NK-cell function through immune training or combination therapy. A single dose of therapeutic Salmonella induced long-lived “trained” NK cells with an epigenetically reprogrammed state characterized by enhanced pro-survival signaling, IFN-γ release, and cytotoxicity upon restimulation; this training depended on a transient IL-12 pulse and sustained IL-18 signaling and outperformed PD-1 and TIGIT blockade in metastasis prevention 42237539Jun. In T-cell acute lymphoblastic leukemia, NK-cell-mediated immunotherapy was evaluated alongside BH3-mimetics, with the study assessing combinations of NK cells with venetoclax, BCL-XL inhibition, MCL-1 inhibition, and dual BCL-2/BCL-XL inhibition, and identifying heterogeneous apoptotic dependencies that influenced sensitivity 41935056Apr.
Several reports addressed NK cells in broader immune modulation and disease settings. Moderate physical activity was investigated for its effects on NK-cell populations and cytotoxic T lymphocytes in young healthy women, reflecting interest in exercise as a modulator of innate and adaptive immunity 42213729May. A mathematical model of IL-6-mediated interactions between NK cells and tumor cells suggested that, under fixed exercise volume, longer exercise bouts may suppress tumors more effectively than higher-frequency shorter bouts 42049052Apr. In irradiated mice, Rehmanniae Radix Praeparata was reported to support immune reconstitution by enhancing IFN-γ production from Th1, Tc1, and NK1 cells and improving NK-cell recovery after radiation-induced injury 42014349Apr.
NK cells were also implicated in innate immune recruitment and tumor microenvironment remodeling. An engineered Bacillus Calmette-Guérin-based implant increased recruitment of M1-type macrophages and NK cells to the tumor site in triple-negative breast cancer models, alongside dendritic cell maturation and downstream activation of cGAS-STING-driven antitumor immunity 41949057Apr. A review of lipid metabolism in the tumor microenvironment described lipid-driven dysfunction of antitumor immune cells, including NK cells, as part of immune evasion in cancer 41946907Apr. In addition, a review on allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia emphasized synergistic interactions between T cells and NK cells in graft-versus-leukemia immunity 41622937Feb.
One toxicology study reported that cannabis joint extract impaired NK-cell viability and function in a dose-dependent manner, primarily through apoptosis. At 3 μg/mL, the extract increased reactive oxygen species, autophagy markers, caspase-3 activation, and DNA damage while reducing mitochondrial membrane potential, and it also diminished NK-cell-mediated killing of HeLa cells without affecting migration or adhesion 42341012Jun.
What Changes, What Holds
1. tumor-localized cytokine delivery strengthens NK-cell antitumor activity without replacing existing checkpoint strategies
REINFORCES Targeted IL-12 delivery adds another way to amplify the antitumor functions already attributed to NK cells in the Overview, especially within the tumor microenvironment. The main implication is translational: localizing activation may preserve efficacy while reducing systemic toxicity, which matters for cytokine-based immunotherapy. The CAR-NK review also supports the existing therapeutic trajectory rather than changing it, while broadening the field toward iPSC manufacturing and autoimmune indications 42302794Jun42034063Apr.
2. NK-cell training can outperform checkpoint blockade for metastasis prevention
REINFORCES Therapeutic bacterial exposure further supports the Overview’s claim that NK cells can enter durable trained states with long-lasting antitumor benefit. What changes is the strength of that trained-state concept: the new work suggests epigenetically reprogrammed NK cells may be more effective than PD-1 or TIGIT blockade in some settings, reinforcing training as a major therapeutic axis rather than a niche phenomenon. The venetoclax/BH3-mimetic study mainly extends combination-immunotherapy thinking 42237539Jun41935056Apr.
3. exercise and supportive interventions remain modulators, but the direction and magnitude are unsettled
REINFORCES Moderate activity and the modeling work fit the established view that exercise can modulate NK-cell biology, but they do not overturn it or define a clinical prescription. The model’s suggestion that bout duration may matter more than frequency is hypothesis-generating, not settled guidance, and the radiation-recovery report adds another supportive intervention for NK-cell restoration after injury. Together these studies sharpen the idea that NK-cell responses are context-sensitive, while leaving optimal exercise or adjunctive regimens unresolved 42213729May42049052Apr42014349Apr.
4. NK cells remain central to tumor recruitment and graft-versus-leukemia immunity, while lipid stress is a new vulnerability
NEW DIRECTION The engineered implant and transplantation review reinforce the Overview’s emphasis on NK cells in tumor control and allogeneic hematopoietic stem cell transplantation. The lipid-metabolism review, however, adds a distinct vulnerability the Overview only hinted at: NK-cell dysfunction driven by lipid-rich tumor environments as a mechanism of immune evasion. That does not displace the established antitumor role, but it does broaden the baseline from activation and enhancement to include metabolic suppression as a major constraint 41949057Apr41946907Apr41622937Feb.
5. Cannabis extract adds a toxicologic liability for NK-cell viability and killing
NEW DIRECTION Cannabis-related injury introduces a harm profile that the Overview does not discuss, so it expands the account rather than contradicting it. The consequence is important for interpretation of NK-cell assays and for any exposure context in which immune competence matters: viability, mitochondrial integrity, and cytotoxic function can all be impaired. Because the baseline makes no positive safety claim here, this is not a reversal of established benefit, but it does identify a new adverse direction for NK-cell biology 42341012Jun.
Overview update candidates: NK-cell dysfunction from lipid metabolism reprogramming in the tumor microenvironment; cannabis extract–induced impairment of NK-cell viability and cytotoxicity.
natural killer cell
Background Contexts
In the literature, the biological baseline, pathological conditions, or disease models commonly surrounding natural killer cell are described as follows:
- tumor microenvironment (Biological Process) — 6 papers: PMIDs 42425951, 42398968, 41949057, 41946907, etc.
- ovarian cancer (Disease) — 4 papers: PMIDs 42454331, 42442222, 42397418, 42387880
- acute myeloid leukemia (Disease) — 3 papers: PMIDs 41928453, 41905408, 41622937
- ALK-mutant neuroblastoma (Disease) — 2 papers: PMIDs 42216567, 42202757
- checkpoint inhibitor (Therapy) — 2 papers: PMIDs 42331382, 41915048
- haematopoietic stem cell transplantation (Therapy) — 2 papers: PMIDs 41995743, 41622937
- IL15 (Protein) — 2 papers: PMIDs 41928453, 41538301
- macrophage (Cellular Component) — 2 papers: PMIDs 41956993, 41915048
- melanoma (Disease) — 2 papers: PMIDs 42397418, 41928453
- metastatic melanoma (Disease) — 2 papers: PMIDs 42052817, 41732954
- NKG2D receptor (Protein) — 2 papers: PMIDs 41656162, 41538301
- non-small-cell lung carcinoma (Disease) — 2 papers: PMIDs 42397418, 41998001
Methodologies & Technologies Used
Researchers utilize the following experimental methods, imaging platforms, computational models, or biological reagents to study natural killer cell:
- 111 DEGs (Gene) — 2 papers: PMIDs 42387880, 42216239
- anti-PD-1 therapy (Therapy) — 2 papers: PMIDs 41915438, 41844941
- B16-F10 melanoma (Organism) — 2 papers: PMIDs 42034063, 42014349
- drug prediction (Other) — 2 papers: PMIDs 42387880, 42113804
- immune infiltration analysis (Technology) — 2 papers: PMIDs 42387880, 42213678
- peripheral blood mononuclear cell (Cell Line) — 2 papers: PMIDs 42449104, 42341012
- transcriptomic and targeted metabolomic analyses (Technology) — 2 papers: PMIDs 42216239, 42213678
- 25-hydroxy vitamin D (Chemical) — 1 paper: PMIDs 41932090
- 96 clinical samples (Other) — 1 paper: PMIDs 42216567
- ACE-iMac (Technology) — 1 paper: PMIDs 41968179
- AddModuleScore (Technology) — 1 paper: PMIDs 42442222
- aggressive pulmonary metastasis (Disease) — 1 paper: PMIDs 41947504
Molecular Interventions & Targets
The primary molecular pathways, regulatory genes, enzymes, or therapeutic agents actively targeted and manipulated in relation to natural killer cell include:
- anti-PD-1 therapy (Therapy) — 2 papers: PMIDs 42071008, 42060360
- cancer-associated fibroblast (Cellular Component) — 2 papers: PMIDs 41946907, 41812066
- carboplatin (Therapy) — 2 papers: PMIDs 42474029, 41732954
- CD8+ S100B+ T cells (Cellular Component) — 2 papers: PMIDs 42213729, 41998001
- HLA-E (Protein) — 2 papers: PMIDs 42425951, 42127218
- KLRC1 (Protein) — 2 papers: PMIDs 42127218, 41998001
- Mitochondrial respiratory chain complex I (Pathway) — 2 papers: PMIDs 42474029, 42442222
- paclitaxel (Therapy) — 2 papers: PMIDs 42474029, 41732954
- pembrolizumab (Therapy) — 2 papers: PMIDs 41915048, 41732954
- programmed cell death 1 (Protein) — 2 papers: PMIDs 42237539, 41587524
- SIGLEC7 (Gene) — 2 papers: PMIDs 41961075, 41928453
- SIGLEC9 (Protein) — 2 papers: PMIDs 41961075, 41928453
Observed Outcomes & Phenotypes
The phenotypic changes, physiological endpoints, or clinical metrics observed and measured in connection with natural killer cell include:
- CD8+ S100B+ T cells (Cellular Component) — 6 papers: PMIDs 42071008, 42052817, 42014349, 41947504, etc.
- IFNG (Protein) — 5 papers: PMIDs 42362557, 42348345, 42237539, 42014349, etc.
- Olatunde Isaac (Cellular Component) — 5 papers: PMIDs 42462479, 42442222, 42173096, 42008343, etc.
- CD4+ and CD8+ T cells (Cell Line) — 3 papers: PMIDs 42307783, 42060360, 41812066
- dendritic cell (Cellular Component) — 3 papers: PMIDs 42449104, 42442222, 42113804
- 1925 DEGs (Biological Process) — 2 papers: PMIDs 42213678, 42113804
- CD4 cell count (Clinical Metric) — 2 papers: PMIDs 42454331, 42362557
- CD4+ effector memory T cells (Cellular Component) — 2 papers: PMIDs 42052817, 42014349
- CD4+CD25+ regulatory T cells (Cellular Component) — 2 papers: PMIDs 42373830, 42014349
- Cytotoxic activity (Clinical Metric) — 2 papers: PMIDs 42365471, 41962724
- cytotoxic T cell (Cellular Component) — 2 papers: PMIDs 42454331, 42399536
- mast cell (Cellular Component) — 2 papers: PMIDs 42213678, 42113804
General Takeaways & Clinical Potentials
The high-level concepts, clinical translations, and overarching conclusions proposed in the research surrounding natural killer cell are summarized below:
- cancer immunotherapy (Biological Process) — 3 papers: PMIDs 42362557, 42060360, 42052817
- C-C motif chemokine ligand 3 (Protein) — 2 papers: PMIDs 41915048, 41732954
- immunomodulation (Other) — 2 papers: PMIDs 41998137, 41946907
- macrophage (Cellular Component) — 2 papers: PMIDs 41587524, 41283998
- prognostic biomarkers (Other) — 2 papers: PMIDs 42307783, 42216239
- adoptive NK transfer (Therapy) — 1 paper: PMIDs 41799416
- advanced and metastatic solid tumors (Disease) — 1 paper: PMIDs 41949057
- advanced-stage OC (Disease) — 1 paper: PMIDs 42387880
- Adverse Events (Other) — 1 paper: PMIDs 41732954
- anti-tumor immunity (Other) — 1 paper: PMIDs 42014349
- antitumor NK cell immunity (Other) — 1 paper: PMIDs 41995743
- autoimmune POI (Disease) — 1 paper: PMIDs 41932090